BI Bags Third Place For Humira Biosimilar in US With AbbVie Pact
Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.
You may also be interested in...
Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.
In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.